Liver Cirrhosis
Pipeline by Development Stage
Drug Modality Breakdown
Gastroenterology is a $7.3B market characterized by mature, blockbuster-driven portfolios with near-term patent cliff risks.
Key Trends
- AbbVie dominance with 43% of top-10 product spending (LINZESS, CREON, RINVOQ)
- Guanylate cyclase activators and JAK inhibitors driving innovation in constipation and IBD
- Multiple patent expirations 2026–2030 creating biosimilar and generic erosion headwinds
Career Verdict
Gastroenterology offers stable, well-compensated roles but limited growth upside; best for risk-averse professionals seeking established markets over innovation-driven career trajectories.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | LINZESS (linaclotide) | AbbVie | $1.8B | 25% | Peak | Stable | 7.7yr |
| 2 | CREON (pancrelipase) | AbbVie | $1.5B | 21% | LOE Approaching | Declining | |
| 3 | XIFAXAN (rifaximin) | Bausch Health | $1.1B | 15% | LOE Approaching | Declining | |
| 4 | RINVOQ (upadacitinib) | AbbVie | $976M | 13% | Peak | Growing | 11.8yr |
| 5 | XELJANZ XR (tofacitinib) | Pfizer | $586M | 8% | Peak | Stable | 8.3yr |
Drug Class Breakdown
mature portfolio anchor
well-established class
facing biosimilar competition
growing IBD adoption
commoditized
Career Outlook
StableGastroenterology is a stable, mature market anchored by blockbusters with long patent runways (LINZESS to 2034, RINVOQ to 2038) but faces near-term erosion (XELJANZ 2026). Employment growth is modest and concentrated in device/diagnostic firms rather than pure-pharma. Best for professionals seeking predictable revenue streams over high-risk innovation bets.
Breaking In
Target roles at Roche, J&J, or diagnostic-adjacent firms to maximize hiring volume; pure pharma gastro entry points at AbbVie/Pfizer are limited and highly competitive.
For Experienced Professionals
Leverage gastro expertise in broader GI/immunology roles (Takeda, Novartis) or transition to medical devices/diagnostics where hiring is 3x higher than pharma.
In-Demand Skills
Best For
Hiring Landscape
Total hiring across the gastro ecosystem is 1,818 jobs, dominated by engineering (434) and commercial roles (269). Roche leads absolute hiring at 377 roles, followed by Johnson & Johnson (323) and GE HealthCare (293), reflecting broad medical device and diagnostic involvement alongside pharma. AbbVie's gastro-specific hiring (78 jobs) is modest relative to its portfolio dominance.
By Department
Manufacturing and commercial roles command premium salaries ($213K and $176K respectively), but total gastro-pharma hiring is concentrated in Roche and J&J, not pure-play GI companies.
Competitive Landscape
25 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 34 trials with date data
Clinical Trials (34)
Total enrollment: 9,356 patients across 34 trials
Effects of Probiotics (BioKid LR - Contains Nine Different Species of Probiotics Bacteria Including L. Reuteri) in Children With Functional Constipation
Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis
Optimized Treatment and Regression of HBV-induced Early Cirrhosis
Intestinal Decontamination With Rifaximin. The Inflammatory and Circulatory State in Patients With Cirrhosis
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients
Antiviral Efficacy, Pharmacokinetics and Safety of BILN 2061 ZW in Patients With Cirrhosis and Chronic Hepatitis C
A Study to Investigate the Blood Concentrations of 4 Different Oral Doses of Zibotentan in Healthy Non-Asian and Japanese Participants
Safety and Tolerability Study of OP-724 in Liver Cirrhosis Patients by HIV/HCV with Hemophilia.
Safety and Efficacy of SHED for Decompensated Liver Cirrhosis
The Tolerability，Safety，PK/PD Study of rhTPO in the Patients With Liver Function Impairment
Use of Gender, Age, Alfa-fetoprotein (AFP), and Des-gamma-carboxyprothrombin (PIVKA-II) or GAAD Score in Addition to Ultrasound for Surveillance of People At-risk for Developing Hepatocellular Carcinoma in Asia in Order to Detect Early Liver Cancer
Utilizing of Physiological Parameters Predict the Prognosis of Cirrhotic Patients With Gastrointestinal Bleeding
EJV Occlusion Pressure Measurement to Assess Intravascular Volume in Cirrhotic Patients During IV Albumin Substitution
Study in Patients With Decompensated Liver Cirrhosis
A Study to Compare How Different Substances (Caffeine, Warfarin, Omeprazole, Metoprolol, and Midazolam) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis
Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk
Multi-analyte Blood Test Clinical Trial
Relevance of Sarcopenia in Advanced Liver Disease
Accuracy of Magnetically Maneuvered Capsule Endoscopy for Detection of EGV in Patients With Cirrhosis
Endosonographic Shear Wave Elastography for Liver Stiffness
Safety and Tolerability of Yaq-001 in Patients With Cirrhosis
Clinical Trial Multi-analyte Blood Test
Alfapump-albumin Replacement Therapy
ALFApump System Post Marketing Surveillance Registry
The Effect of Probiotics on Lactose Intolerance
Probiotics for Liver Cirrhosis With Portal Hypertension
Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis
Effects on Plasma Exchange on Functional Capacity of Serum Albumin, Circulatory Dysfunction, Renal and Cerebral Function in Cirrhotic Patients With "Acute-on-chronic Liver Failure"
Transient Elastography in Autoimmune Hepatitis
Probiotics for the Prevention of Major Complications of Cirrhosis
Related Jobs in Gastroenterology
Director, Marketing Operations
Area Business Manager - Central Alabama
Grants Manager
Quality Assurance Lead - FvP
Quality Compliance Lead International
Associate Director, Pharmacovigilance (PV) Commercial Liaison, Global Clinical Safety and Pharmacovigilance
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.